[
  {
    "ts": null,
    "headline": "Amgen (AMGN): Examining Valuation After Recent 6% Share Price Rise",
    "summary": "Amgen (AMGN) shares have quietly edged up in recent days, with the stock gaining around 6% over the past week. Investors appear to be considering the company’s stable financials and long-term performance as they evaluate what comes next. See our latest analysis for Amgen. Amgen’s share price has shown steady upward momentum lately, and this recent rally builds on what’s been a largely resilient run. Despite a flat 1-year total shareholder return, the company boasts a robust 3-year total...",
    "url": "https://finnhub.io/api/news?id=cb135a74e6a2db54fccd8f841e0bf6940378e57916fbc962e3ff28e958fac3ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759422100,
      "headline": "Amgen (AMGN): Examining Valuation After Recent 6% Share Price Rise",
      "id": 136960200,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) shares have quietly edged up in recent days, with the stock gaining around 6% over the past week. Investors appear to be considering the company’s stable financials and long-term performance as they evaluate what comes next. See our latest analysis for Amgen. Amgen’s share price has shown steady upward momentum lately, and this recent rally builds on what’s been a largely resilient run. Despite a flat 1-year total shareholder return, the company boasts a robust 3-year total...",
      "url": "https://finnhub.io/api/news?id=cb135a74e6a2db54fccd8f841e0bf6940378e57916fbc962e3ff28e958fac3ed"
    }
  },
  {
    "ts": null,
    "headline": "Why Amgen (AMGN) is a Top Momentum Stock for the Long-Term",
    "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
    "url": "https://finnhub.io/api/news?id=b94491eca7dd2a57d233541cecc744900a6a5e8ca486747ef8d296bbcfd7e90c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759413002,
      "headline": "Why Amgen (AMGN) is a Top Momentum Stock for the Long-Term",
      "id": 136960201,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
      "url": "https://finnhub.io/api/news?id=b94491eca7dd2a57d233541cecc744900a6a5e8ca486747ef8d296bbcfd7e90c"
    }
  },
  {
    "ts": null,
    "headline": "Stocks making big moves yesterday: ZoomInfo, Dave, Atkore, Saia, and Amgen",
    "summary": "Check out the companies making headlines yesterday:",
    "url": "https://finnhub.io/api/news?id=155ccb0d27aae4b92d528053d5f81fd200d05b98828b8e3f4ca1a5ff0185be6e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759410038,
      "headline": "Stocks making big moves yesterday: ZoomInfo, Dave, Atkore, Saia, and Amgen",
      "id": 136960202,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Check out the companies making headlines yesterday:",
      "url": "https://finnhub.io/api/news?id=155ccb0d27aae4b92d528053d5f81fd200d05b98828b8e3f4ca1a5ff0185be6e"
    }
  },
  {
    "ts": null,
    "headline": "LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS",
    "summary": "Amgen (NASDAQ:AMGN) today announced the Phase 3 VESALIUS-CV clinical trial met its dual primary endpoints demonstrating that Repatha® (evolocumab) significantly reduced the risk of major adverse cardiovascular events (MACE) in individuals without a prior history of heart attack or stroke. The landmark Phase 3 VESALIUS-CV trial enrolled over 12,000 high-risk patients, approximately 85% of whom were maintained on a high-intensity or moderate low-density lipoprotein cholesterol (LDL-C) reducing the",
    "url": "https://finnhub.io/api/news?id=bd96f7353752473b23b2a95783c5ece02c0d159ae9e28915b6f2fa9b99c1e841",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759410000,
      "headline": "LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS",
      "id": 136955452,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ:AMGN) today announced the Phase 3 VESALIUS-CV clinical trial met its dual primary endpoints demonstrating that Repatha® (evolocumab) significantly reduced the risk of major adverse cardiovascular events (MACE) in individuals without a prior history of heart attack or stroke. The landmark Phase 3 VESALIUS-CV trial enrolled over 12,000 high-risk patients, approximately 85% of whom were maintained on a high-intensity or moderate low-density lipoprotein cholesterol (LDL-C) reducing the",
      "url": "https://finnhub.io/api/news?id=bd96f7353752473b23b2a95783c5ece02c0d159ae9e28915b6f2fa9b99c1e841"
    }
  },
  {
    "ts": null,
    "headline": "Amgen claims ‘landmark’ study result that could widen heart drug’s use",
    "summary": "In a first-of-its-kind finding, Amgen’s PCSK9 drug protected heart health when tested as a “primary prevention” therapy, which could pave the way for access to a much broader population.",
    "url": "https://finnhub.io/api/news?id=b045d0c90753a6b93da33fd6e56212354562981b35ed3ca932dc750ffb9d612d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759405980,
      "headline": "Amgen claims ‘landmark’ study result that could widen heart drug’s use",
      "id": 136960203,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "In a first-of-its-kind finding, Amgen’s PCSK9 drug protected heart health when tested as a “primary prevention” therapy, which could pave the way for access to a much broader population.",
      "url": "https://finnhub.io/api/news?id=b045d0c90753a6b93da33fd6e56212354562981b35ed3ca932dc750ffb9d612d"
    }
  },
  {
    "ts": null,
    "headline": "Amgen's Repatha Phase 3 Trial Meets Dual Primary Endpoints",
    "summary": "Amgen's Repatha Phase 3 Trial Meets Dual Primary Endpoints",
    "url": "https://finnhub.io/api/news?id=9d4ccde12187b5a4b6bee872a2f926ea842c1c71aa3061704fb03514b516a75e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759397280,
      "headline": "Amgen's Repatha Phase 3 Trial Meets Dual Primary Endpoints",
      "id": 137016657,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Amgen's Repatha Phase 3 Trial Meets Dual Primary Endpoints",
      "url": "https://finnhub.io/api/news?id=9d4ccde12187b5a4b6bee872a2f926ea842c1c71aa3061704fb03514b516a75e"
    }
  },
  {
    "ts": null,
    "headline": "2 High-Yield Dividend Growth Stocks to Buy in October and Hold for a Decade or Longer",
    "summary": "These stocks have been raising their payouts much faster than most dividend payers.",
    "url": "https://finnhub.io/api/news?id=8dbebb9cbbb00ebb30d8ab96224457379cdc0855876f2179aa5ada49f440255f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759389960,
      "headline": "2 High-Yield Dividend Growth Stocks to Buy in October and Hold for a Decade or Longer",
      "id": 136955453,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "These stocks have been raising their payouts much faster than most dividend payers.",
      "url": "https://finnhub.io/api/news?id=8dbebb9cbbb00ebb30d8ab96224457379cdc0855876f2179aa5ada49f440255f"
    }
  },
  {
    "ts": null,
    "headline": "Bruce Beutler Unlocked Key Mystery To Disease — And He's Not Done",
    "summary": "Bruce Beutler Unlocked Key Mystery To Disease — And He's Not Done",
    "url": "https://finnhub.io/api/news?id=bc6d96bd330e09030ca4bafc2fb23f323cc37989ecdacbc804bf16bdefea3d47",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759388444,
      "headline": "Bruce Beutler Unlocked Key Mystery To Disease — And He's Not Done",
      "id": 137016636,
      "image": "",
      "related": "AMGN",
      "source": "DowJones",
      "summary": "Bruce Beutler Unlocked Key Mystery To Disease — And He's Not Done",
      "url": "https://finnhub.io/api/news?id=bc6d96bd330e09030ca4bafc2fb23f323cc37989ecdacbc804bf16bdefea3d47"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc (AMGN) Ramps Up Manufacturing Capacity in US, Amidst Hefty Tariffs",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the Top Blue Chip Stocks to Buy At 52-Week Lows. On September 26, Reuters reported that global drugmakers are rushing to increase their manufacturing capacity in the United States as the Trump administration is imposing hefty tariffs on pharmaceutical imports. As a result, Amgen Inc. (NASDAQ:AMGN) is also ramping […]",
    "url": "https://finnhub.io/api/news?id=393b37d19f781e5e93c7fd259eac13ea6af3b8e444f71281d53ef3120d6873fb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759388148,
      "headline": "Amgen Inc (AMGN) Ramps Up Manufacturing Capacity in US, Amidst Hefty Tariffs",
      "id": 136955454,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the Top Blue Chip Stocks to Buy At 52-Week Lows. On September 26, Reuters reported that global drugmakers are rushing to increase their manufacturing capacity in the United States as the Trump administration is imposing hefty tariffs on pharmaceutical imports. As a result, Amgen Inc. (NASDAQ:AMGN) is also ramping […]",
      "url": "https://finnhub.io/api/news?id=393b37d19f781e5e93c7fd259eac13ea6af3b8e444f71281d53ef3120d6873fb"
    }
  },
  {
    "ts": null,
    "headline": "Amgen (AMGN) Announces $650M Puerto Rico Facility Expansion",
    "summary": "Amgen Inc. (NASDAQ:AMGN) ranks among the top picks for a retirement portfolio. On September 26, Amgen Inc. (NASDAQ:AMGN) unveiled a $650 million upgrade to its manufacturing facility in Juncos, Puerto Rico, which is estimated to create around 750 additional jobs. The investment will help to improve medicine production capacities and incorporate innovative technology across the […]",
    "url": "https://finnhub.io/api/news?id=dbf668d835d620ffc1225c5ffa9c439f67ab9bd3c747149e659a2deb42ba70fb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759386811,
      "headline": "Amgen (AMGN) Announces $650M Puerto Rico Facility Expansion",
      "id": 136955455,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc. (NASDAQ:AMGN) ranks among the top picks for a retirement portfolio. On September 26, Amgen Inc. (NASDAQ:AMGN) unveiled a $650 million upgrade to its manufacturing facility in Juncos, Puerto Rico, which is estimated to create around 750 additional jobs. The investment will help to improve medicine production capacities and incorporate innovative technology across the […]",
      "url": "https://finnhub.io/api/news?id=dbf668d835d620ffc1225c5ffa9c439f67ab9bd3c747149e659a2deb42ba70fb"
    }
  }
]